研究单位：[1]GeneScience Pharmaceuticals Co., Ltd.[2]TongJi hospital affiliated to TongJi medical college of HuaZhong university of Science & Teconology Wuhan, Hubei, China
研究目的：
To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period
To explore the factors influencing the efficacy of PEG-Somatropin and to establish the height prediction model based on Chinese children with short stature, and to provide the basis and guidance for standard and reasonable long-term clinical application of PEG-Somatropin.
